Loading stock data…
$11.91+0.15 (+1.32%)
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States.
Ginkgo Bioworks Holdings, Inc. in the Healthcare sector is trading at $11.91 with a market capitalization of $471M. Wall Street consensus targets $8.00 (2 analysts), implying a -32.9% move over the next 12 months. The stock is currently 35% below its 52-week high of $18.22, remaining 40.5% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $20.16M↑ | $19.47M↓ | $33.40M↓ | $38.84M↓ | $39.13M |
| Gross Profit | $18.44M↑ | $16.38M↓ | $26.09M↑ | $26.04M↓ | $33.75M |
| Operating Income | -$58.55M↑ | -$71.37M↓ | -$70.05M↑ | -$88.27M↓ | -$54.60M |
| Net Income | -$46.71M↑ | -$82.59M↓ | -$80.75M | -$80.75M↓ | -$60.30M |
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and develop...